Soft Tissue, Phase II
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
What is the purpose of this trial?
This phase II trial studies how well atezolizumab works in treating patients with alveolar soft part sarcoma that has not been treated, has spread from where it started to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as atezolizumab, may allow the immune system cells to find and kill the tumor cells.
- Trial withNational Cancer Institute (NCI)
- Ages18 years and older
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact email@example.com, or call 877.978.8343 for more information.
- Last Updated03/30/2023
- Study HIC#2000021392